Last reviewed · How we verify
CAIV-T or TIV
CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.
CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses. Used for Seasonal influenza prevention in children and adults aged 2-49 years.
At a glance
| Generic name | CAIV-T or TIV |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened live influenza virus strains that replicate in the nasal mucosa, triggering both local IgA antibody production and systemic cellular immunity without causing disease. This approach provides broader and more durable protection compared to inactivated vaccines, particularly against mismatched strains.
Approved indications
- Seasonal influenza prevention in children and adults aged 2-49 years
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
- Myalgia
Key clinical trials
- Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) (PHASE2)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older (PHASE2)
- Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAIV-T or TIV CI brief — competitive landscape report
- CAIV-T or TIV updates RSS · CI watch RSS
- MedImmune LLC portfolio CI